ReviewCurrent oncology reports2026
Advances in Single-Cell and Spatial Omics for Glioblastoma Precision Medicine.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGlioblastoma is the most aggressive and fatal primary malignant brain tumour in adults, characterised by extensive intra-tumour heterogeneity, diffuse infiltration into surrounding brain tissue. Despite advances in surgery, radiotherapy, and chemotherapy, patient prognosis remains poor, underscoring the critical need for improved biological insight to guide precision medicine potential strategies. Although traditional bulk genomic and transcriptomic analyses have made a substantial contribution to understanding glioblastoma pathophysiology, such average molecular signals across cell populations obscures tumour microenvironment influence and clinically significant cellular states. RECENT
findingsRecent advances in single-cell and spatial omics technologies have revolutionised glioblastoma research by enabling high-resolution analysis of tumour composition, cellular plasticity, and spatial organisation. These modalities have revealed that glioblastoma is composed of dynamic and plastic cellular states as opposed to fixed molecular subtypes, including stem-like and therapy-resistant populations that contribute to recurrence. The tumour architecture is preserved by spatially resolved transcriptomic and proteomic approaches, which reveal regional transcriptional programmes influenced by the tumour ecosystem. The findings provide a more resolved view of glioblastoma evolution and treatment resistance, challenging current classification systems. However, significant challenges remain in integrating these high-dimensional datasets, managing technical and computational demands, and translating these approaches into clinically scalable workflows which collectively hinder their translational adoption. This review aims to synthesise recent advances in glioblastoma single-cell and spatial omics, critically evaluating both advantages and limitations in understanding tumour heterogeneity and tumour microenvironmental interactions. Furthermore, it assesses the current challenges of glioblastoma precision medicine and evaluates the potential of these technologies to advance such approaches.
Indexed as
Identifiers
42911458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.